HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Clinical efficacy of a petroleum-derived product (Larimsh) used as compassionate treatment in patients with terminal prostate cancer.

Abstract
Treatment of a light fraction of petroleum treated by metallic catalysis results in a liquid mixture of low molecular weight compounds named LarimshTM (LR). Acute and chronic topical treatment of mice with LR (85 days with 0.1 to 1 mL/animal) indicated no signs of toxicity other than a non dose-dependent, reversible alopecia appearing by the 4th week of topical application. Alopecia completely reversed 2 weeks after treatment withdrawal. Acute oral LR (0.001 to 1 mL; the lowest doses diluted in corn oil as vehicle) gave an estimated LD50 of 21 g/kg (C.I. 95 %: 10.94-41.2 g/kg. LR density = 0.867 g/mL). The antineoplastic action of LR was observed using combined oral and topical treatments in mice; inoculated with a lymphoid leukemia cell line in ascitic phase (International Registry L5178Y); and in terminal patients with prostate cancer (TPCA)--who agreed to receive LR as a compassionate treatment. The survival time for mice was significantly increased when compared with non-treated inoculated mice (51 +/- 2 versus 38 +/- 2 days, p < 0.05, mean +/- SD, N = 6 per group). In 15 patients, LR treatment for 5.5 months (C.I. 95 %: 2.9 to 8.0 months) significantly increased the expected survival time diagnosed to TPCA by their treating physicians (C.I. 95 %: 2.2 to 5.4 versus 12.6 to 41.2 months, p < 0.05) which occurred concomitantly with a significant reduction of blood levels of total prostatic antigen (average 94.5%, range: 67.3 to 99.9%). A theoretical proposal is advanced as a likely explanation of LR actions.
AuthorsRafaín Rodríguez-Pérez, Maritza García-Montañez, Humberto Lemus-Balcazar, Marcos DeLaRosa Viejo, Jaime Grijalva-Monreal, Andrés E Castell-Rodríguez, María Dolores Ramírez-González
JournalProceedings of the Western Pharmacology Society (Proc West Pharmacol Soc) Vol. 50 Pg. 143-51 ( 2007) ISSN: 0083-8969 [Print] United States
PMID18605253 (Publication Type: Journal Article)
Chemical References
  • Petroleum
  • larimsh
  • Prostate-Specific Antigen
Topics
  • Animals
  • Bone and Bones (radionuclide imaging)
  • Cell Line, Tumor
  • Chromatography, Gas
  • Dose-Response Relationship, Drug
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Middle Aged
  • Palliative Care
  • Petroleum (analysis)
  • Prostate-Specific Antigen (blood)
  • Prostatic Neoplasms (radionuclide imaging, therapy)
  • Quality Control
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD